What to Expect on Wegovy: Your First Weeks and Beyond

What happens in the first few weeks of Wegovy?

The very first thing most people notice is not weight loss, it is food. Portions that felt normal suddenly feel generous. The urge to snack between meals quietens. Some people describe eating half a plate and feeling done. This is semaglutide doing its job: slowing how quickly food leaves the stomach and activating GLP-1 receptors that communicate fullness to the brain.

Week 1 starts at 0.25 mg, a dose chosen entirely for tolerability. The first week on Wegovy is your system adjusting, not a measure of how the treatment will eventually work. Nausea is the most commonly reported side effect at this stage, usually mild and often tied to eating too quickly or choosing richer foods. Staying well hydrated and eating smaller, simpler meals can help.

By week two, many people find the nausea settles. Energy can dip temporarily as calorie intake falls. This is normal. The NHS notes that gastrointestinal side effects are most common when starting or after a dose increase, and typically improve within days to two weeks. Keep your pen stored in the fridge door alongside everyday items, the routine of seeing it helps most people stay consistent with their weekly dose day.

Actual weight on the scales tends to shift noticeably from weeks three to six, as the lower calorie intake compounds over time. For a closer look at that mid-titration window, week five on Wegovy is when many people first describe feeling genuinely settled on the treatment.

How does weight loss progress as the dose increases?

Wegovy follows a stepped schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg) with roughly four weeks at each level. The prescriber guides this; the pace is not something to rush. Each increase can bring a brief return of nausea or digestive disruption, then a further dip in appetite and another phase of weight loss. Understanding that rhythm makes the ups and downs easier to navigate.

The clinical evidence is clear on what the full schedule can achieve. In the STEP 1 trial, published in the New England Journal of Medicine, adults with obesity who took semaglutide 2.4 mg for 68 weeks lost an average of approximately 15% of their starting body weight, compared with around 2.4% in the placebo group. That is a substantial, clinically meaningful difference, and it was achieved alongside lifestyle changes, not instead of them.

For a more detailed breakdown of how long Wegovy takes to work at each stage, including what the trial data says about the timeline to different weight-loss thresholds, that page covers it fully. The short version: most people see clear progress by month two or three; the bulk of total weight loss typically occurs between months three and twelve.

What side effects should you be prepared for on Wegovy?

Gastrointestinal effects are the most common: nausea, loose stools or constipation, indigestion, burping, and occasionally vomiting. Fatigue and mild headaches are reported less often. These are predictable, dose-related effects, they follow the curve of each titration step and generally settle within one to two weeks. They are rarely a reason to stop; slowing the titration pace is sometimes the better clinical response, which is a conversation for your prescriber.

A small number of people experience more significant GI upset, which can lead to dehydration if left unmanaged. Seek medical advice promptly if you cannot keep fluids down for more than a day or two. The MHRA also highlighted acute pancreatitis as a known but infrequent serious risk with GLP-1 medicines in its January 2026 Drug Safety Update: severe, persistent stomach pain that radiates to the back (with or without vomiting) warrants urgent medical assessment, not a wait-and-see approach.

Side effects can also be reported directly to the MHRA via the Yellow Card scheme. This matters, real-world reporting contributes to ongoing safety monitoring for medicines still under additional MHRA surveillance, as Wegovy currently is.

For a full picture of what the experience of taking Wegovy involves day to day, this guide to taking Wegovy covers the practical details from injection technique to what to do if a weekly dose is missed.

Does Wegovy work for everyone, and when should you reassess?

Not everyone responds to semaglutide in the same way. NICE guidance on semaglutide (TA875) recommends that if less than 5% weight loss has occurred after six months at the maintenance dose, continuing the treatment should be reviewed with a clinician. That threshold is not a failure, it is a built-in checkpoint to make sure the medicine is earning its place in your care.

Individual factors (starting weight, diet quality, activity levels, sleep, other medicines, and underlying conditions) all shape the outcome. The clinical trials involve large populations; averages do not predict individual results. What they do show is a strong, consistent signal of meaningful weight reduction for people who stay on treatment and engage with lifestyle changes alongside it.

On the Wegovy pricing page you can find current cost information for private treatment, including what is included in a legitimate, clinically supervised prescription. If you are already on treatment elsewhere and thinking about transferring, our clinical team reviews transfer patients in the same way as new starts, individually, with evidence of current dose and treatment history.

If you are considering whether Wegovy might be right for you, start your free consultation and a GPhC-registered prescriber will review your details the same day.